View in EDS PDF Full Text

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
Authors: Perugino C; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA., Culver EL; Translational Gastroenterology Unit, John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, UK., Khosroshahi A; Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, USA., Zhang W; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China., Della-Torre E; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Hospital, Milan, Italy., Okazaki K; Department of Internal Medicine, Kansai Medical University Kori Hospital, Osaka, Japan., Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan., Löhr M; Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden., Schleinitz N; Département de Medecine Interne, CHU Timone, AP-HM, Aix-Marseille Université, Marseille, France., Falloon J; Horizon Therapeutics, Rockville, MD, USA., She D; Horizon Therapeutics, Rockville, MD, USA., Cimbora D; Horizon Therapeutics, Rockville, MD, USA., Stone JH; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. jhstone@mgh.harvard.edu.; Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Suite Yawkey 4, Boston, MA, 02114, USA. jhstone@mgh.harvard.edu.
Source: Rheumatology and therapy [Rheumatol Ther] 2023 Dec; Vol. 10 (6), pp. 1795-1808. Date of Electronic Publication: 2023 Oct 04.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Country of Publication: England NLM ID: 101674543 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2198-6576 (Print) Linking ISSN: 21986576 NLM ISO Abbreviation: Rheumatol Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37792260
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Perugino+C%22">Perugino C</searchLink>; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Culver+EL%22">Culver EL</searchLink>; Translational Gastroenterology Unit, John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Khosroshahi+A%22">Khosroshahi A</searchLink>; Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Della-Torre+E%22">Della-Torre E</searchLink>; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Hospital, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Okazaki+K%22">Okazaki K</searchLink>; Department of Internal Medicine, Kansai Medical University Kori Hospital, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Tanaka+Y%22">Tanaka Y</searchLink>; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.<br /><searchLink fieldCode="AU" term="%22Löhr+M%22">Löhr M</searchLink>; Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Schleinitz+N%22">Schleinitz N</searchLink>; Département de Medecine Interne, CHU Timone, AP-HM, Aix-Marseille Université, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Falloon+J%22">Falloon J</searchLink>; Horizon Therapeutics, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22She+D%22">She D</searchLink>; Horizon Therapeutics, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Cimbora+D%22">Cimbora D</searchLink>; Horizon Therapeutics, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Stone+JH%22">Stone JH</searchLink>; Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. jhstone@mgh.harvard.edu.; Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Suite Yawkey 4, Boston, MA, 02114, USA. jhstone@mgh.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101674543%22">Rheumatology and therapy</searchLink> [Rheumatol Ther] 2023 Dec; Vol. 10 (6), pp. 1795-1808. <i>Date of Electronic Publication: </i>2023 Oct 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare%22">Springer Healthcare </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101674543 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2198-6576 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221986576%22">21986576 </searchLink><i>NLM ISO Abbreviation: </i>Rheumatol Ther <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37792260
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40744-023-00593-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1795
    Titles:
      – TitleFull: Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Perugino C
      – PersonEntity:
          Name:
            NameFull: Culver EL
      – PersonEntity:
          Name:
            NameFull: Khosroshahi A
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Della-Torre E
      – PersonEntity:
          Name:
            NameFull: Okazaki K
      – PersonEntity:
          Name:
            NameFull: Tanaka Y
      – PersonEntity:
          Name:
            NameFull: Löhr M
      – PersonEntity:
          Name:
            NameFull: Schleinitz N
      – PersonEntity:
          Name:
            NameFull: Falloon J
      – PersonEntity:
          Name:
            NameFull: She D
      – PersonEntity:
          Name:
            NameFull: Cimbora D
      – PersonEntity:
          Name:
            NameFull: Stone JH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2023 Dec
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2198-6576
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Rheumatology and therapy
              Type: main
ResultId 1